Study of ‘Vivalan’ in Geriatric Patients Suffering from Depression

Abstract

Twenty elderly depressed patients were entered into a study of Vivalan (viloxazine; 150–200 mg daily). Significant falls in Hamilton and Zung ratings occurred by Day 7 of treatment and further significant improvements were noted over the following 2 weeks. These changes were also reflected in global assessments. Headache was reported in six patients and nausea in three. Vivalan had no significant effect upon blood pressure and absence of anticholinergic side-effects proved an advantage in the treatment of elderly patients with depressive illness.